Table 2 Study characteristics
| Â | Authors | Year | Country | Type of STI | Perspective | Type of intervention | Comparator | Type of analysis* | Type of study | Outcome(s) | Year of valuation | Currency |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Adamson et al. | 2019 | USA | HIV | Multiple (Societal, Healthcare) | Financial incentives for HIV viral suppression | Standard of care | CEA | Disease progression model and ongoing transmission | QALYs, viral suppression, reduced HIV infections prevented | 2017 | USD |
2 | Campos et al. | 2021 | USA | HPV | Modified payer perspective | HPV testing self-collection at home | Standard of care involving cytology and HPV co-testing at the Health Department clinics | CEA | Monte Carlo microsimulation model/ micro-costing study alongside RCT | Year of life saved | 2019 | USD |
3 | Coupe et al. | 2009 | NL | HPV | Societal | Cervical cancer screening strategies | Vaccination only | Not explicitly stated | Markov simulation model | QALYs | 2006 | EUR |
4 | Damm et al. | 2017 | GER | HPV | Multiple (Societal, Healthcare) | Vaccination in addition to screening | Screening alone | Not explicitly stated | Dynamic transmission model (SIRS) | LYs, QALYs | 2010 | EUR |
5 | De Kok et al. | 2009 | NL | HPV | Societal | Vaccination in addition to cervical cancer screening | Screening alone | CEA | Simulation model (MISCAN) | QALYs, CIN lesions detected, cervical cancer diagnosis, cervical cancer deaths, life-years lost | 2008 | EUR |
6 | De Wit et al. | 2015 | NL | Chlamydia | Societal | Screening (six scenarios) | Another scenario, or no screening | Not explicitly stated | Analogous to the transmission dynamics model | QALYs | 2010 | EUR |
7 | Deogan et al. | 2010 | SWE | Chlamydia | Societal | Community based intervention (testing, treatment, contact tracing) | No intervention | CEA | Cost-effectiveness model | QALYs, reduced potential costs associated with medical sequels | 2007 | EUR |
8 | Drabo et al. | 2016 | USA | HIV | Societal | Testing (expanded), test-and-treat (expanded HIV testing combined with immediate treatment) and PrEP | Status quo | CEA | Economic model following a compartmental HIV transmission model | QALYs, HIV incidence | 2010; 2013 | USD |
9 | Fogelberg et al. | 2020 | SWE | HPV | Societal | Alternative screening strategies | Alternative screening strategies | CEA | Microsimulation model | QALE, measured in terms of QALYs, incorporating disutility due to cervical cancer | 2014 | SEK to EUR |
10 | Gift et al. | 2011 | USA | Chlamydia, Gonorrhoea | Multiple (Societal, Payer, Healthcare) | Expedited partner treatment (EPT) | Unassisted standard partner referral (SR) | Not explicitly stated | Monte Carlo simulation model | QALYs | 2008 | USD |
11 | Ginsberg et al. | 2020 | ISR | HIV | Societal | PrEP use by MSM | No PrEP | CUA | Model (Excel-based) | DALYs | 2018 | USD |
12 | Kim et al. | 2009 | USA | HPV | Societal | Vaccination and cervical cancer screening in older women | Screening alone | CEA | Monte Carlo simulation model | QALYs, reductions in lifetime risk for cervical cancer | 2006 | USD |
13 | Kim & Goldie | 2009 | USA | HPV | Societal | Vaccination of girls and boys | screening alone; HPV vaccination of girls alone | CEA | Dynamic transmission model, incidence based models | QALYs, outcomes related to cervical disease and other cancers associated with HPV 16/18, HPV 6/11 associated genital warts, juvenile onset recurrent respiratory papillomatosis | 2006 | USD |
14 | Krauth et al. | 2020 | GER | Hepatitis C | Societal | HCV screening strategies (including MSM as a target group) | No screening | Not explicitly stated | Markov Model | QALYs | 2015 | EUR |
15 | Mahumud et al. | 2019 | AUS | HPV | Multiple (Societal, Health System) | HPV vaccination | Three different vaccine delivery strategies | CEA | Papillomavirus Rapid Interface for Modelling and Economics (PRIME) model | DALYs, LYs | 2018 | AUD |
16 | Nosyk et al. | 2015 | CAN | HIV | Multiple (Societal, Third-party payer) | Population-level HAART expansion (testing and treatment) | Constrained treatment access to HAART (75, 50%) | CEA | Dynamic compartmental transmission model | QALYs, HIV prevalence, incidence | 2010 | CAD |
17 | Ouellet et al. | 2015 | CAN | HIV | Societal | On-demand PrEP | Lifetime costs of HIV infection | CEA | Model based on clinical trial | QALYs, LYs | 2012 | CAD |
18 | Owusu-Edusei et al. [45] | 2015 | USA | Chlamydia | Societal | Vaccination | Various strategies of i.e. no screening, no vaccination, tailored screening | Not explicitly stated | Compartmental heterosexual transmission model | QALYs | 2013 | USD |
19 | Owusu-Edusei et al. [46] | 2016 | USA | Chlamydia | Societal | Opt-Out Chlamydia Testing | Risk-based screening (status quo) | Not explicitly stated | Compartmental heterosexual transmission model | QALYs | 2014 | USD |
20 | Regnier et al. | 2014 | USA | Gonorrhoea | Societal | Vaccination (meningococcal) | Standard of care (antibiotics) | Not explicitly stated | Decision-analysis model | QALYs | 2012 | USD |
21 | Rogoza et al. | 2009 | NL | HPV | Societal | Vaccination on top of screening | NCCSP only | Not explicitly stated | Markov model | QALYs, LYs | 2009 | EUR |
22 | Rossi et al. | 2013 | CAN | Hepatitis B | Societal | Universal vaccination, screening & vaccination, screening & treatment, combined screening | No targeted screening or vaccination | CEA | Markov model (decision-tree) | QALYs, HBV-associated morbidity and mortality | 2011 | CAD |
23 | Rours et al. | 2016 | NL | Chlamydia | Societal | Antenatal screening | No screening | CEA | Decision-analysis model | QALYs, pregnancy outcomes averted | 2009 | EUR |
24 | Van Luenen et al. | 2019 | NL | HIV | Societal | Guided Internet-based intervention | Attention only | CUA | Trial | QoL, QALYs | 2017 | EUR |
25 | Van Wifferen et al. | 2021 | NL | Chlamydia, Gonorrhoeae | Societal | Screening strategies 6 monthly | Screening strategies 3 monthly (current practice) | CEA | Dynamic infection model | QALYs, prevalence of chlamydia and gonorrhoea | 2018 | EUR |
26 | Wijnen et al. | 2019 | NL | HIV | Societal | Adherence Improving Self-management Strategy in HIV Care | Treatment as usual | CEA, CUA | Markov Model | QALYs | 2013 | EUR |
27 | Wolff et al. | 2018 | SWE | HPV | Multiple (Societal, Healthcare) | Sex-neutral vaccination | Girls-only vaccination | Not explicitly stated | Epidemiological model; Dynamic compartmental model (HPV-related cancers) | QALYs | 2018 | EUR |
28 | Zechmeister et al. | 2009 | AT | HPV | Multiple (Societal, Public payer) | Vaccination in addition to screening for girls only Vaccination in addition to screening for girls and boys | Screening only | CEA | Dynamic transmission model | LYG | 2007 | EUR |
29 | Zulliger et al. | 2017 | USA | HIV | Multiple (Societal, Payer) | HIV testing and linkage to care | 5 main testing strategies | CUA | Trial | QALYs | 2013 | USD |